Article thumbnail

Malarial parasite pathogenesis and drug targets

By Paul D Roepe


This report highlights recent insights into malarial parasite pathogenesis that are relevant for new antimalarial drug discovery

Topics: Review Article
Publisher: Biology Reports Ltd
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). A clinical drug library screen identifies astemizole as an antimalarial agent.
  2. (2005). Bioavailable iron and heme metabolism in Plasmodium falciparum. Curr Top Microbiol Immunol
  3. (2006). DeRisi JL: Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des
  4. (2007). Drug discovery for malaria: a very challenging and timely endeavor. Curr Opin Chem Biol
  5. (2008). F: Hyper-reactive malarial splenomegaly in a patient with human immunodeficiency virus. Am J Trop Med Hyg
  6. (2008). KN: Hyperreactive malarial splenomegaly is associated with low levels of antibodies against red blood cell and Plasmodium falciparum derived glycolipids in Yanomami Amerindians from Venezuela. Acta Trop
  7. (2005). Kremsner PG: Uncomplicated malaria. Curr Top Microbiol Immunol
  8. (2003). LH: Plasmodium biology: genomic gleanings. Cell
  9. (2008). Louw AI: Exploring functional genomics for drug target and therapeutics discovery in Plasmodia. Acta Trop
  10. (2008). Malarial proteases and host cell egress: an 'emerging' cascade. Cell Microbiol
  11. (2007). Meijer L: Antimalarial drug discovery: targeting protein kinases. Expert Opin Ther Targets
  12. (2007). Mitochondrial drug targets in apicomplexan parasites. Curr Drug Targets
  13. (2007). NC: Recent advances in malaria drug discovery. Recent Pat Antiinfect Drug Discov
  14. (2005). Negative epistasis between the malariaprotective effects of alpha +-thalassemia and the sickle cell trait. Nat Genet
  15. (2008). Overcoming drug resistance to heme-targeted antimalarials by systematic side chain variation of 7-chloro-4-aminoquinolines.
  16. (2006). PE: Plasmodium falciparum: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta. Exp Parasitol
  17. (2008). Roepe PD: 4-N-, 4-S-, and 4-O-chloroquine analogues: influence of side chain length and quinolyl nitrogen pKa on activity vs chloroquine resistant malaria.
  18. (2008). Roepe PD: Stage independent chloroquine resistance and chloroquine toxicity revealed via spinning disk confocal microscopy. Mol Biochem Parasitol
  19. (2007). Rosenthal PJ: World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria.
  20. (2008). SH: Malaria parasite pre-erythrocytic stage infection: gliding and hiding. Cell Host Microbe
  21. (2008). SN: The acidocalcisome as a target for chemotherapeutic agents in protozoan parasites. Curr Pharm Des
  22. (2005). ST: Fatty Acid synthesis as a target for antimalarial drug discovery. Comb Chem High Throughput Screen
  23. (2007). TE: Malaria: mechanisms of erythrocytic infection and pathological correlates of severe disease. Annu Rev Pathol
  24. (2003). The apicoplast: a plastid in Plasmodium falciparum and other Apicomplexan parasites. Int Rev Cytol
  25. (2008). Tokunaga K: A functional single-nucleotide polymorphism in the CR1 promoter region contributes to protection against cerebral malaria. J Infect Dis
  26. (2008). TV: Plasmodium falciparum: growth response to potassium channel blocking compounds. Exp Parasitol
  27. (2004). WB: Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev
  28. (2005). Wellems TE: Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature
  29. (2008). Winzeler EA: In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.